S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
FENC · Fennec Pharmaceuticals Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Fennec Pharmaceuticals Inc (FENC)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$10.38
-0.09
(-0.81%)
● At close: October 21 at 4:00:00 PM EDT
$10.38
+0.00
(+0.00%)
After-Hours:
4:01:37 PM EDT
DAY'S RANGE
$10.38
$10.29
$10.65
52-WEEK RANGE
$10.38
$5.65
$13.25
What's happening
- FENC is down 0.81% today, trading at $10.38. — Live quote
- Volume today (2,808) is well below its 3-month average of 204,950. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $0.05 actual vs. $0.01 estimated (+400.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
FENC
+35.84%
vs S&P 500
+23.07%
1-YEAR RETURN
FENC
+20.79%
vs S&P 500
+6.22%
6-MONTH RETURN
FENC
+66.03%
3-MONTH RETURN
FENC
+0.67%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$0.05
Est. $0.01
BEAT +400.0%
2026-04-26 (Q1 2026)
$0.01
Est. $-0.01
BEAT +217.6%
2026-01-26 (Q4 2025)
$-0.10
Est. $0.04
MISS -380.1%
2025-10-26 (Q3 2025)
$-0.02
Est. $-0.02
BEAT +8.3%
Valuation Measures & Ratios
Enterprise Value4$325.0M
Forward P/E514.69
PEG Ratio6—
Price / Sales (TTM1)6.18
Price / Book78.80
EV4 / Revenue5.49
EV4 / EBITDA115.01
Profit Margin-5.49%
Operating Margin-5.31%
Return on Equity (ROE8)-6.78%
Return on Assets (ROA9)-4.86%
Avg Volume (3M)204,950
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $423.8M | $123.7M | $292.8M | $240.4M | $178.5M |
| P/E | -262.25 | -26.02 | -27.39 | -15.41 | 464.94 |
| Price/Sales | 7.69 | 2.69 | 7.74 | 7.37 | 3.69 |
| Price/Book | 9.99 | 3.28 | -65.19 | -32.21 | -30.36 |
| EV/Revenue | 6.94 | 1.82 | 7.67 | 7.39 | 3.62 |
| ROE | -3.81% | -12.62% | 237.98% | 209.10% | -6.53% |
| ROA | -2.13% | -6.62% | -21.70% | -34.77% | 0.83% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short513,287
Change from Prior Settlement-5.83%
% of Float—
Days to Cover (Short Ratio)3.85
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 72.6% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +20.8%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -5.5%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on FENC
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.9M | $15.1M | $12.5M | $9.7M | $8.8M | $7.0M | $7.3M | $25.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $1.7M | -$119.0K | -$189.0K | -$2.7M | -$808.0K | -$5.2M | -$5.0M | $13.7M |
| Net income | $2.0M | $201.0K | -$638.0K | -$3.2M | -$1.2M | -$5.7M | -$5.6M | $12.8M |
| EPS (diluted) | $0.05 | $0.01 | $-0.02 | $-0.11 | $-0.04 | $-0.21 | $-0.20 | $0.41 |
| EPS (basic) | $0.06 | $0.01 | $-0.02 | $-0.11 | $-0.04 | $-0.21 | $-0.20 | $0.47 |
| Operating margin | $10 | -$1 | -$2 | -$28 | -$9 | -$75 | -$69 | $54 |
| Net margin | $11 | $1 | -$5 | -$33 | -$13 | -$82 | -$76 | $51 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $75.8M | $71.8M | $70.6M | $49.3M | $44.9M | $46.4M | $44.9M | $58.9M |
| Total liabilities | $33.3M | $34.1M | $35.1M | $53.8M | $52.3M | $52.3M | $50.8M | $64.1M |
| Stockholders' equity | $42.4M | $37.7M | $35.5M | -$4.5M | -$7.5M | -$5.9M | -$5.9M | -$5.2M |
| Total current assets | $72.5M | $66.9M | $67.0M | $46.1M | $40.8M | $43.0M | $44.1M | $58.0M |
| Total current liabilities | $12.4M | $9.6M | $10.5M | $9.8M | $8.4M | $8.4M | $6.9M | $7.4M |
| Cash & equivalents | $41.2M | $40.2M | $36.8M | $21.9M | $18.7M | $22.7M | $26.6M | $40.3M |
| Other current assets | $2.0M | $2.6M | $1.7M | $898.0K | $965.0K | $1.0M | $466.0K | $546.0K |
| Other non-current assets | $666.0K | $691.0K | $717.0K | $743.0K | $768.0K | $794.0K | $822.0K | $956.0K |
| Accounts payable | $5.5M | $6.3M | $4.6M | $5.9M | $5.9M | $5.3M | $3.2M | $3.9M |
| Accrued liabilities | $3.7M | $3.1M | $5.6M | $3.7M | $2.2M | $2.8M | $3.4M | $3.3M |
| Deferred revenue (current) | $3.2M | $248.0K | $248.0K | $248.0K | $248.0K | $248.0K | $248.0K | $248.0K |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | $19.4M | $19.4M | $19.4M | $19.3M | $32.1M |
| Common stock & paid-in capital | $193.2M | $191.2M | $189.9M | $147.7M | $146.2M | $146.0M | $145.6M | $145.4M |
| Retained earnings | -$227.2M | -$229.2M | -$229.4M | -$224.6M | -$224.0M | -$220.8M | -$219.7M | -$217.7M |
| Accumulated other comprehensive income (loss) | $1.2M | $1.2M | $1.2M | $1.2M | $1.2M | $1.2M | $1.2M | $1.2M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $50.0K | $2.4M | -$6.0M | $1.5M | -$3.7M | -$4.3M | -$1.5M | -$2.2M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | $1.0M | $1.0M | $20.8M | $1.7M | -$284.0K | $359.0K | -$12.2M | -$528.0K |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Share-based compensation | $1.8M | $990.0K | $2.5M | $2.2M | $1.5M | $798.0K | $1.1M | $1.8M |
| Change in accounts receivable | $4.2M | -$4.5M | $3.5M | $3.4M | $265.0K | $5.3M | $175.0K | $4.2M |
| Change in inventory | $518.0K | $291.0K | -$139.0K | $276.0K | $797.0K | $344.0K | -$65.0K | -$502.0K |
| Change in accounts payable | -$765.0K | $1.6M | -$1.2M | -$75.0K | $661.0K | $2.0M | -$626.0K | -$580.0K |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | $19.5M | — | — | — | $13.0M | — |
| Tax withholding on stock comp | $941.0K | $311.0K | $26.0K | $50.0K | $99.0K | $12.0K | $9.0K | $58.0K |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $44.6M | $47.5M | $21.3M | $1.5M | — |
| Gross profit | — | — | $20.0M | $1.4M | — |
| Operating income | -$6.3M | $2.6M | -$12.8M | -$22.6M | -$17.2M |
| Net income | -$9.7M | -$436.0K | -$16.0M | -$23.7M | -$17.3M |
| EPS (diluted) | $-0.34 | $-0.02 | $-0.60 | $-0.90 | $-0.67 |
| EPS (basic) | $-0.34 | $-0.02 | $-0.60 | $-0.90 | $-0.67 |
| Operating margin | -$14 | $5 | -$60 | -$1.5K | — |
| Net margin | -$22 | -$1 | -$75 | -$1.5K | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Sep '23 | Dec '22 |
|---|---|---|---|---|---|
| Total assets | $70.6M | $44.9M | $26.9M | $20.0M | $26.9M |
| Total liabilities | $35.1M | $50.8M | $38.5M | — | $29.5M |
| Stockholders' equity | $35.5M | -$5.9M | -$11.6M | $9.6M | -$2.6M |
| Total current assets | $67.0M | $44.1M | $26.9M | $19.9M | $26.7M |
| Total current liabilities | $10.5M | $6.9M | $7.6M | — | $4.6M |
| Cash & equivalents | $36.8M | $26.6M | $13.3M | — | $23.8M |
| Other current assets | $1.7M | $466.0K | $44.0K | — | $63.0K |
| Other non-current assets | $717.0K | $822.0K | $816.0K | — | — |
| Accounts payable | $4.6M | $3.2M | $3.8M | — | $2.4M |
| Accrued liabilities | $5.6M | $3.4M | $3.8M | — | $2.2M |
| Deferred revenue (current) | $248.0K | $248.0K | — | — | — |
| Long-term debt | — | $19.3M | $30.9M | — | $24.9M |
| Common stock & paid-in capital | $189.9M | $145.6M | $144.3M | — | $142.6M |
| Retained earnings | -$229.4M | -$219.7M | -$219.2M | $215.6M | -$203.2M |
| Accumulated other comprehensive income (loss) | $1.2M | $1.2M | $1.2M | — | $1.2M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$12.5M | $27.0M | -$17.1M | -$18.1M | -$14.2M |
| Investing cash flow | — | — | — | — | — |
| Financing cash flow | $22.6M | -$13.6M | $6.6M | $20.7M | $5.0M |
| Capital expenditures | — | — | — | — | — |
| Share-based compensation | $7.0M | $5.1M | $5.4M | $4.1M | $3.7M |
| Change in accounts receivable | $12.4M | $7.9M | $7.3M | $1.5M | — |
| Change in inventory | $1.3M | -$579.0K | $1.6M | $576.0K | — |
| Change in accounts payable | $1.4M | -$537.0K | $1.4M | $1.6M | -$794.0K |
| Debt issued | — | — | $5.0M | $24.9M | $5.0M |
| Debt repaid | $19.5M | $13.0M | — | $5.0M | — |
| Tax withholding on stock comp | $187.0K | $176.0K | $78.0K | $194.0K | — |
| Other financing activities | — | — | $3.0K | $238.0K | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding FENC as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-07-31 to 2026-10-12
Recent transactions
- Insiders have net sold 122,545 shares over the last 182 days, across 0 purchases and 5 sales.
- Most recent: Sayad Pierre Sargis (Chief Medical Officer) — Grant / award of 3,846 shares on 2026-10-12.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)122,545 sh(5 txns)
Net Shares-122,545
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Sayad Pierre Sargis | Chief Medical Officer | Grant / award | 2026-10-12 | 3,846 |
| Hackman Jeffrey S. | Chief Executive Officer | Grant / award | 2026-10-12 | 2,224 |
| Evans Terry L | Chief Commercial Officer | Grant / award | 2026-10-12 | 2,326 |
| Cioffi Christiana Marie | Chief Strategy Officer | Grant / award | 2026-10-12 | 3,946 |
| Andrade Robert | CHIEF FINANCIAL OFFICER | Grant / award | 2026-10-12 | 3,846 |
| Brughera Marco Maria | Reporting person | Option exercise | 2026-09-15 | 15,545 |
| Raykov Rosty | Reporting person | Open market sale | 2026-09-01 | 10,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-12 | Sayad Pierre Sargis | Chief Medical Officer | Grant / award | 3,846 | $5.53 |
| 2026-10-12 | Hackman Jeffrey S. | Chief Executive Officer | Grant / award | 2,224 | $5.53 |
| 2026-10-12 | Evans Terry L | Chief Commercial Officer | Grant / award | 2,326 | $5.53 |
| 2026-10-12 | Cioffi Christiana Marie | Chief Strategy Officer | Grant / award | 3,946 | $5.53 |
| 2026-10-12 | Andrade Robert | CHIEF FINANCIAL OFFICER | Grant / award | 3,846 | $5.53 |
| 2026-09-30 | Sayad Pierre Sargis | Chief Medical Officer | Grant / award | 168 | $0.00 |
| 2026-09-30 | Evans Terry L | Chief Commercial Officer | Grant / award | 168 | $0.00 |
| 2026-09-30 | Hackman Jeffrey S. | Chief Executive Officer | Grant / award | 1,159 | $0.00 |
| 2026-09-30 | Cioffi Christiana Marie | Chief Strategy Officer | Grant / award | 156 | $0.00 |
| 2026-09-30 | Andrade Robert | CHIEF FINANCIAL OFFICER | Grant / award | 1,703 | $0.00 |
| 2026-09-15 | Brughera Marco Maria | Reporting person | Option exercise | 15,545 | $2.11 |
| 2026-09-15 | Brughera Marco Maria | Reporting person | Open market sale | 15,545 | $10.29 |
| 2026-09-01 | Raykov Rosty | Reporting person | Open market sale | 10,000 | $12.11 |
| 2026-08-31 | Raykov Rosty | Reporting person | Grant / award | 2,778 | $0.00 |
| 2026-08-31 | Sayad Pierre Sargis | Chief Medical Officer | Grant / award | 168 | $0.00 |
| 2026-08-31 | Sayad Pierre Sargis | Chief Medical Officer | Open market sale | 12,000 | $12.18 |
| 2026-08-31 | Evans Terry L | Chief Commercial Officer | Grant / award | 168 | $0.00 |
| 2026-08-31 | Cioffi Christiana Marie | Chief Strategy Officer | Grant / award | 156 | $0.00 |
| 2026-08-31 | Hackman Jeffrey S. | Chief Executive Officer | Grant / award | 1,159 | $0.00 |
| 2026-08-31 | Andrade Robert | CHIEF FINANCIAL OFFICER | Grant / award | 1,703 | $0.00 |
| 2026-08-28 | Andrade Robert | CHIEF FINANCIAL OFFICER | Option exercise | 21,928 | $5.10 |
| 2026-08-27 | Andrade Robert | CHIEF FINANCIAL OFFICER | Open market sale | 75,000 | $11.78 |
| 2026-08-03 | Raykov Rosty | Reporting person | Open market sale | 10,000 | $9.58 |
| 2026-07-31 | Sayad Pierre Sargis | Chief Medical Officer | Grant / award | 168 | $0.00 |
| 2026-07-31 | Evans Terry L | Chief Commercial Officer | Grant / award | 168 | $0.00 |
| 2026-07-31 | Cioffi Christiana Marie | Chief Strategy Officer | Grant / award | 156 | $0.00 |
| 2026-07-31 | Hackman Jeffrey S. | Chief Executive Officer | Grant / award | 1,159 | $0.00 |
| 2026-07-31 | Raykov Rosty | Reporting person | Grant / award | 2,778 | $0.00 |
| 2026-07-31 | Andrade Robert | CHIEF FINANCIAL OFFICER | Grant / award | 1,703 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:09 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-09-17 | 8-K | 2026-09-17 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-15 | View on SEC.gov → |
Recent news
Headlines about FENC (Fennec Pharmaceuticals Inc.). Links open the publisher — we don’t host full articles.
-
A passive holder reports sole voting power over 2.5M Fennec Pharmaceuticals (FENC) shares.
Stock Titan · 2026-10-19 -
(FENC) Movement Within Algorithmic Entry Frameworks
Stock Traders Daily · 2026-10-17 -
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
Yahoo Finance · 2026-09-17 -
Fennec: The Turnaround Is Real, But The Stock Prices In Perfection (Downgrade)
Seeking Alpha · 2026-08-12 -
Fennec Pharmaceuticals Inc (FENC) (Q2 2026) Earnings Call Highlights: Record Sales and ...
Yahoo Finance · 2026-08-11 -
Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript
Seeking Alpha · 2026-08-11 -
Fennec Pharmaceuticals surges 8% as Q2 earnings and revenue beat estimates
Yahoo Finance · 2026-08-11 -
Fennec Pharmaceuticals GAAP EPS of $0.05 beats by $0.04, revenue of $17.87M beats by $1.75M
Seeking Alpha · 2026-08-11
No headlines in this category right now — try “All”.